Literature DB >> 23179177

Drug use in patients with dementia: a register-based study in the health region of Girona (Catalonia/Spain).

Pilar Avila-Castells1, Josep Garre-Olmo, Laia Calvó-Perxas, Oriol Turró-Garriga, Elisabet Alsina, Olga Carmona, Héctor Perkal, Anna Maria Roig, Josep Ma Cuy, Manuela Lozano, Albert Molins, Natàlia Vallmajó, Secundino López-Pousa.   

Abstract

PURPOSE: To describe the pattern of drug consumption among patients with dementia in a geographically defined general population in Catalonia (Spain), and to determine its association with age, gender, type of dementia and severity indicators.
METHODS: Cross-sectional study that included 1,894 cases of dementia registered by the Registry of Dementias of Girona from 2007 to 2009. Prescribed drugs were categorized according to the Anatomical Therapeutic Chemical (ATC) classification. A descriptive analysis of drug consumption was stratified according to age, gender, dementia subtypes and dementia severity. Binary logistic regression models were adjusted to detect the association of these variables with drug consumption according to the ATC groups.
RESULTS: The most commonly prescribed drugs were for the central nervous system (CNS) (96.4 %), cardiovascular system (79.4 %) and digestive and metabolic system categories (77.7 %). No significant differences were found between the use of nervous system drugs and age, gender, dementia subtypes or dementia severity. The use of alimentary tract and metabolism related drugs, as well as cardiovascular and blood system drugs, were positively correlated with age and secondary dementia. The prevalence of use of cardiovascular and musculoskeletal drugs was higher in women than in men (OR: 1.34; OR: 1.26 respectively). A negative association was found between the severity of dementia and the use of musculoskeletal drugs (OR: 0.71), while its use was significantly higher in the youngest patients (OR: 1.71).
CONCLUSIONS: Almost all patients with dementia received a CNS drug, being at risk of inappropriate treatment. Treatment for comorbidities in patients with dementia should not be withheld on the basis of age or dementia severity, but rather on the benefit/risk ratio of its prescription. Further studies are needed to evaluate potentially inappropriate drug use and possible untreated conditions in this population.

Entities:  

Mesh:

Year:  2012        PMID: 23179177     DOI: 10.1007/s00228-012-1451-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  49 in total

1.  Global prevalence of dementia: a Delphi consensus study.

Authors:  Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

2.  The world of dementia beyond 2020.

Authors:  Henry Brodaty; Monique M B Breteler; Steven T Dekosky; Pascale Dorenlot; Laura Fratiglioni; Christoph Hock; Paul-Ariel Kenigsberg; Philip Scheltens; Bart De Strooper
Journal:  J Am Geriatr Soc       Date:  2011-04-13       Impact factor: 5.562

3.  Dementia management programme in a community setting and the use of psychotropic drugs in the elderly population.

Authors:  Erik Jedenius; Kristina Johnell; Johan Fastbom; Jan Strömqvist; Bengt Winblad; Niels Andreasen
Journal:  Scand J Prim Health Care       Date:  2011-07-11       Impact factor: 2.581

4.  Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors.

Authors:  H Brodaty; B Draper; D Saab; L F Low; V Richards; H Paton; D Lie
Journal:  Int J Geriatr Psychiatry       Date:  2001-05       Impact factor: 3.485

5.  The consumption of drugs by 75-year-old individuals living in their own homes.

Authors:  I Barat; F Andreasen; E M Damsgaard
Journal:  Eur J Clin Pharmacol       Date:  2000-09       Impact factor: 2.953

6.  Medication errors in elderly people: contributing factors and future perspectives.

Authors:  Daniela Fialová; Graziano Onder
Journal:  Br J Clin Pharmacol       Date:  2009-06       Impact factor: 4.335

7.  STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation.

Authors:  P Gallagher; C Ryan; S Byrne; J Kennedy; D O'Mahony
Journal:  Int J Clin Pharmacol Ther       Date:  2008-02       Impact factor: 1.366

8.  Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia.

Authors:  Renate M Nijk; Sytse U Zuidema; Raymond T C M Koopmans
Journal:  Int Psychogeriatr       Date:  2009-04-16       Impact factor: 3.878

9.  [High prevalence of neuroleptic drug use in elderly people with dementia].

Authors:  Isabel Fort; Francesc Formiga; María José Robles; Pedro Regalado; Daniel Rodríguez; Elena Barranco
Journal:  Med Clin (Barc)       Date:  2009-11-11       Impact factor: 1.725

10.  Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial.

Authors:  Bettina S Husebo; Clive Ballard; Reidun Sandvik; Odd Bjarte Nilsen; Dag Aarsland
Journal:  BMJ       Date:  2011-07-15
View more
  4 in total

1.  Prevalence of oral anticoagulant use among people with and without Alzheimer's disease.

Authors:  Barkat Ali Babar; Mai Vu; Marjaana Koponen; Heidi Taipale; Antti Tanskanen; Raimo Kettunen; Miia Tiihonen; Sirpa Hartikainen; Anna-Maija Tolppanen
Journal:  BMC Geriatr       Date:  2022-05-28       Impact factor: 4.070

2.  Treatment Patterns with Antidementia Drugs in the United States: Medicare Cohort Study.

Authors:  Daniela Koller; Tammy Hua; Julie P W Bynum
Journal:  J Am Geriatr Soc       Date:  2016-06-24       Impact factor: 5.562

3.  Syndrome-Based Prescription to Optimize Psychotropics: Are CHROME Criteria a Game Changer?

Authors:  Ruben Muñiz; Jorge López-Alvarez; Luis Agüera-Ortiz; Luis Perea; Javier Olazarán
Journal:  Front Psychiatry       Date:  2021-04-22       Impact factor: 4.157

4.  CHROME Criteria and Quality of Life: A Pilot Study from Maria Wolff-Albertia.

Authors:  Ruben Muñiz; Jorge López-Álvarez; Luis Perea; Sofía Rivera; Liliana González; Javier Olazarán
Journal:  J Alzheimers Dis Rep       Date:  2021-08-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.